Panna Sharma
President, CEO & Director
Okay. Thank you, everyone, for joining us today for our LP-184 clinical trial results webinar. We’ll be talking in depth today with some of our Lantern’s team and also with our collaborator and partner in developing the trial and some of the early science behind LP-184. Dr. Igor Astsaturov from Fox Chase is also on with us as well. I’m going to be talking about an overall, the drug just to give everyone an overview of the molecule. And then we’ll be talking about the scientific background and some of the early development to give people an appreciation for the molecule. And then we’ll be digging right into the clinical results from the trial and some of the observations that we’ve made.
We’ve got a lot of information to present and walk through today. So I appreciate everyone’s patience, and we’ll take some time for Q&A toward the end. If you have questions, definitely send them into the chat window, and we’ll be selecting questions to go through. With that, I’m going to introduce our panelists today. We’ve got our Chief Scientific Officer, Dr. Kishor Bhatia. We have our Head of Clinical Development, Dr. Reggie Ewesuedo. And as I mentioned, also, we have Dr. Igor Astsaturov from Fox Chase who’s been our collaborator in the development of the molecule.
So with that, let’s talk a little bit about 184. 184 is being aimed primarily for the treatment of advanced solid tumors, largely focused on tumors that are deficient in
